{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:30:15Z","timestamp":1793287815629,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","award":["K12 CA133250"],"award-info":[{"award-number":["K12 CA133250"]}],"id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002733"],"award-info":[{"award-number":["UL1TR002733"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008747","name":"Center for Clinical and Translational Science, Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K12 CA133250"],"award-info":[{"award-number":["K12 CA133250"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cllc.2021.12.010","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T22:14:48Z","timestamp":1641593688000},"page":"345-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Yizhen","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-3828","authenticated-orcid":false,"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2583-2394","authenticated-orcid":false,"given":"Tyler","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha P.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Spakowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9877-8512","authenticated-orcid":false,"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-1921","authenticated-orcid":false,"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-5639","authenticated-orcid":false,"given":"Carolyn","family":"Presley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Coss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-5280","authenticated-orcid":false,"given":"Mitch A.","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-4886","authenticated-orcid":false,"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2021.12.010_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.cllc.2021.12.010_bib0002","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.12.010_bib0004","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.12.010_bib0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cllc.2021.12.010_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"10.1016\/j.cllc.2021.12.010_bib0008","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00345-016-1940-1","article-title":"Prognostic value of the glasgow prognostic score in renal cell carcinoma: a meta-analysis","volume":"35","author":"Shim","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.cllc.2021.12.010_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/jcm10051005","article-title":"The Gustave Roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line Pembrolizumab","volume":"10","author":"Lenci","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.cllc.2021.12.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100254","article-title":"Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer","volume":"6","author":"Mountzios","year":"2021","journal-title":"ESMO open"},{"key":"10.1016\/j.cllc.2021.12.010_bib0011","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.amjcard.2019.11.006","article-title":"Effect of serum albumin levels in patients with heart failure with preserved ejection fraction (from the TOPCAT trial)","volume":"125","author":"Prenner","year":"2020","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.cllc.2021.12.010_bib0012","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.3390\/ijms22094496","article-title":"Hypoalbuminemia as surrogate and culprit of infections","volume":"22","author":"Wiedermann","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.cllc.2021.12.010_bib0013","doi-asserted-by":"crossref","first-page":"e0217006","DOI":"10.1371\/journal.pone.0217006","article-title":"Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock","volume":"14","author":"Jantti","year":"2019","journal-title":"Plos One"},{"key":"10.1016\/j.cllc.2021.12.010_bib0014","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/ecco-jcc\/jjz083","article-title":"Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: the NSQIP Surgical Cohort","volume":"13","author":"Nguyen","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.cllc.2021.12.010_bib0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1186\/s12885-017-3814-3","article-title":"Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status","volume":"17","author":"Ikeda","year":"2017","journal-title":"Bmc Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-10-50","article-title":"Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study","volume":"10","author":"Arrieta","year":"2010","journal-title":"Bmc Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0017","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/1759-7714.13788","article-title":"Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab","volume":"12","author":"Araki","year":"2021","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2021.12.010_bib0018","doi-asserted-by":"crossref","first-page":"e001674","DOI":"10.1136\/jitc-2020-001674","article-title":"Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer","volume":"8","author":"Johannet","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0019","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.21873\/anticanres.13262","article-title":"Post-treatment glasgow prognostic score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1","volume":"39","author":"Kasahara","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2021.12.010_bib0020","first-page":"E437","article-title":"Pretreatment serum prealbumin as an independent prognostic indicator in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors as first-line target therapy","volume":"15","author":"Cai","year":"2017","journal-title":"Clin Genitourin Canc"},{"key":"10.1016\/j.cllc.2021.12.010_bib0021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4149\/318_151001N512","article-title":"Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib","volume":"63","author":"Fiala","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.cllc.2021.12.010_bib0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2152\/jmi.61.361","article-title":"Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study","volume":"61","author":"Ishida","year":"2014","journal-title":"J Med Investig"},{"key":"10.1016\/j.cllc.2021.12.010_bib0023","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/000313481708301123","article-title":"Hypoalbuminemia and clinical outcomes: what is the mechanism behind the relationship?","volume":"83","author":"Kim","year":"2017","journal-title":"Am Surg"},{"key":"10.1016\/j.cllc.2021.12.010_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/IJGM.S102819","article-title":"Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements","volume":"9","author":"Levitt","year":"2016","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.cllc.2021.12.010_bib0025","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1016\/j.ejim.2018.04.016","article-title":"Hypoalbuminemia is related to inflammation rather than malnutrition in sarcoidosis","volume":"53","author":"Mirsaeidi","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.cllc.2021.12.010_bib0026","doi-asserted-by":"crossref","first-page":"1023.E1","DOI":"10.1016\/j.amjmed.2015.03.032","article-title":"Serum albumin and prealbumin in calorically restricted, nondiseased individuals: a systematic review","volume":"128","author":"Lee","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.cllc.2021.12.010_bib0027","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/10640260902991202","article-title":"Serum albumin levels may not correlate with weight status in severe anorexia nervosa","volume":"17","author":"Narayanan","year":"2009","journal-title":"Eat Disord"},{"key":"10.1016\/j.cllc.2021.12.010_bib0028","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00000658-199802000-00015","article-title":"Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response","volume":"227","author":"Fearon","year":"1998","journal-title":"Annals of surgery"},{"key":"10.1016\/j.cllc.2021.12.010_bib0029","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ibd\/izz143","article-title":"Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease","volume":"26","author":"Bauman","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cllc.2021.12.010_bib0030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00280-014-2560-3","article-title":"Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors","volume":"74","author":"Garg","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2021.12.010_bib0031","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cllc.2021.12.010_bib0032","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-021-09739-y","article-title":"Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies","volume":"48","author":"Yang","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cllc.2021.12.010_bib0033","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/psp4.12406","article-title":"Time-Varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma","volume":"8","author":"Wilkins","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cllc.2021.12.010_bib0034","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.xphs.2018.10.064","article-title":"Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non-small cell lung cancer","volume":"108","author":"Li","year":"2019","journal-title":"J Pharm Sci-Us"},{"key":"10.1016\/j.cllc.2021.12.010_bib0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/psp4.12477","article-title":"Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors","volume":"9","author":"Sanghavi","year":"2020","journal-title":"Cpt-Pharmacomet Syst"},{"key":"10.1016\/j.cllc.2021.12.010_bib0036","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/psp4.12476","article-title":"Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies","volume":"8","author":"Zhang","year":"2019","journal-title":"Cpt-Pharmacomet Syst"},{"key":"10.1016\/j.cllc.2021.12.010_bib0037","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cpt.982","article-title":"Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status","volume":"103","author":"Baverel","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cllc.2021.12.010_bib0038","doi-asserted-by":"crossref","first-page":"jcs235416","DOI":"10.1242\/jcs.235416","article-title":"FcRn mediates fast recycling of endocytosed albumin and IgG from early macropinosomes in primary macrophages","volume":"133","author":"Toh","year":"2020","journal-title":"J Cell Sci"},{"key":"10.1016\/j.cllc.2021.12.010_bib0039","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/bcp.13996","article-title":"Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology","volume":"85","author":"Bajaj","year":"2019","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.cllc.2021.12.010_bib0040","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cllc.2021.12.010_bib0041","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2021.12.010_bib0042","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.2147\/CMAR.S261585","article-title":"Cancer cachexia: definition, staging, and emerging treatments","volume":"12","author":"Ni","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cllc.2021.12.010_bib0043","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2021.12.010_bib0044","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/rco2.32","article-title":"Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans","volume":"4","author":"Castillo","year":"2021","journal-title":"JCSM Rapid Commun"},{"key":"10.1016\/j.cllc.2021.12.010_bib0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.12.010_bib0046","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1016\/j.cllc.2021.12.010_bib0047","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0048","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0049","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.21037\/jtd.2020.02.27","article-title":"The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab","volume":"12","author":"Matsubara","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2021.12.010_bib0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"Jama Oncol"},{"key":"10.1016\/j.cllc.2021.12.010_bib0051","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.2017.480","article-title":"Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials","volume":"118","author":"Sen","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0052","first-page":"709","article-title":"Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: a network meta-analysis of randomized trials","volume":"127","author":"Pathak","year":"2021","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.cllc.2021.12.010_bib0053","first-page":"5569","article-title":"Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy","volume":"28","author":"Jiang","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0054","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/01635581.2020.1769691","article-title":"The role of a cachexia grading system in patients with non-small cell lung cancer treated with immunotherapy: implications for survival","volume":"73","author":"Turcott","year":"2021","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.cllc.2021.12.010_bib0056","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcsm.12161","article-title":"Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy","volume":"8","author":"Chu","year":"2017","journal-title":"J Cachexia Sarcopeni"},{"key":"10.1016\/j.cllc.2021.12.010_bib0057","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jcsm.12436","article-title":"Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients","volume":"10","author":"Kurk","year":"2019","journal-title":"J Cachexia Sarcopeni"},{"key":"10.1016\/j.cllc.2021.12.010_bib0058","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jcsm.12391","article-title":"Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study","volume":"10","author":"da Rocha","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cllc.2021.12.010_bib0059","unstructured":"FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression \u22651%). Accessed from:https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1.Accessed at: February 27, 2021."},{"key":"10.1016\/j.cllc.2021.12.010_bib0060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study","volume":"10","author":"Morimoto","year":"2021","journal-title":"Oncoimmunology"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:51:52Z","timestamp":1778521912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1525730422000080"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.12.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}